PERSONAL HISTORY
`
`BUSINESS ADDRESS
`
`
`
`
`
`CURRICULUM VITAE
`
`MAHMOUD A. GHANNOUM, M.Sc., Ph.D., EMBA
`
`Professor and Director,
`Center for Medical Mycology and Mycology Reference
`Laboratory
`Department of Dermatology
`Case Western Reserve University and
`University Hospitals Case Medical Center
`11100 Euclid Avenue, LKS 5028
`Cleveland, Ohio 44106-5028
`(216) 844-8580 (Telephone)
`(216) 844-1076 (Fax)
`
`May 7, 1950
`
`Beirut, Lebanon
`
`US
`
`Married
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`DATE OF BIRTH
`
`PLACE OF BIRTH
`
`CITIZENSHIP
`
`MARITAL STATUS
`
`EDUCATION
`
`
`
`
`American University of Beirut, Beirut, Lebanon
`
`B.Sc., 1973
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Loughborough University of Technology, Loughborough,
`England,
`M.Sc., 1974
`
`Loughborough University of Technology, Loughborough,
`England
`Ph.D., 1978
`
`Yeast Genetics Course, Cold Spring Harbor Laboratories,
`Cold Spring Harbor, July - August, 1993
`
`Weatherhead School of Management,
`Case Western Reserve University,
`Cleveland, OH, USA,
`Executive MBA, 2004
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 1/62
`
`

`
`PROFESSIONAL EXPERIENCE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Tenured Professor, Department of Dermatology,
`Case Western Reserve University, 2000-present
`
`Director, Center for Medical Mycology and the Mycology
`Reference Laboratory,
`Case Western Reserve and
`University Hospitals Case Medical Center, 1996-present
`
`Professor, Secondary Appointment, Department of Pathology,
`
`Case Western Reserve University
`
`Professor, Secondary Appointment, Bioinformatics and
`
`Proteomic Center, Case Western Reserve University
`
`Associate Professor, Department of Dermatology at Case
`Western Reserve University, 1996-2000
`
`Adjunct Professor of Medicine, Step II, Division of Infectious
`Diseases,
`Harbor-UCLA and UCLA School of Medicine, 1994-1996
`
`Research Mycologist, Step II, Division of Infectious Diseases,
`Harbor-UCLA and UCLA School of Medicine, 1994
`
`Research Mycologist, Step I, Division of Infectious Diseases,
`Harbor-UCLA and UCLA School of Medicine, 1991-1994
`
`Professor of Microbial Physiology, Department of Botany &
`Microbiology, Kuwait University, 1990 – 1991
`
`Associate Professor, Department of Botany & Microbiology,
`Kuwait University, 1985 –1990
`
`Assistant Professor, Department of Botany & Microbiology,
`Kuwait University, 1980 –1985
`
`Assistant Professor, Higher Institute of Technology, Malta, 1978-
`1980
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 2/62
`
`

`
`PROFESSIONAL ACTIVITIES
`
`COMMITTEES
`
`-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`-
`
`-
`
`-
`
`-
`-
`-
`-
`
`-
`
`-
`
`-
`
`-
`-
`
`-
`-
`-
`
`-
`-
`
`-
`
`-
`
`-
`
`-
`
`-
`
`
`Chairman, Oral HIV/AIDS Research Alliance (OHARA),
`2010-2013
`OHARA Representative, Scientific Agenda Steering
`Committee, 2010-present
`OHARA Representative, AIDS Clinical Trial Group (ACTG)
`ACTG Executive Committee 2010-2013
`- Member, Repository Advisory Group, 2010-2013
`- Chairman, Sub-Committee on Antifungal Susceptibility
`Testing, Clinical and Laboratory Standards Institute (CLSI),
`2010-present
`Member, Institute of Infectious Diseases and Immunology,
`School of Medicine, 2011-present
`Member, Outside Interest Committee, Case
`Member, Space Committee, School of Medicine, Case
`Chair, Recruitment Committee, Department of Dermatology
`Chair, Committee on Appointment, Promotions and
`
`Tenure, Department of Dermatology
`Ad-Hoc Member, Drug Discovery and Resistance Study
`Section, NIH
`Member, Review Committee, Burroughs Wellcome
`Foundation
`Chair, Clinical and Laboratory Standards Institute (CLSI)
`Antifungal Susceptibility Subcommittee
`President, Medical Mycological Society of Americas (MMSA)
`Member, Editorial Board, Antimicrobial Agents and
`
`Chemotherapy
`Member, Editorial Board, Journal of Chemotherapy
`Member, Editorial Board, Journal of Clinical Microbiology
`Member, Scientific Committee, Trends in Medical Mycology
`Conference, Valencia, Spain
`Member, Outside Interest Committee, 2008-present
`Case Member, High Throughput Screening Committee,
`Technology Transfer Office, Case, 2012-present
`Member, Executive Committee, Infectious Diseases and
`Immunology Institute, School of Medicine, 2012- present
`Leading the effort to establish the Infectious Disease Drug
`Development Center, CWRU and University Hospitals Case
`Medical Center, 2012- present
`Chair, Recruitment Committee, Department of Dermatology,
`2008- present
`Chair, Committee on Appointment, Promotions and Tenure,
`Department of Dermatology, 2008-present
`Director, Clinical Research Core, Department of
`Dermatology
`
`
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 3/62
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Vice-Chair-holder, NIH Subcommittee on Antifungal
`Susceptibility tests as of January 2008
`Chairman, Department of Dermatology Committee on
`Appointments, Promotions and Tenure, CWRU, current
`Chairman and organizer of Symposium on Biofilms for the
`2008 XIIth IUMS Congress, Istanbul, current
`Steering Committee of the OHARA Subcommittee of OPMAN,
`current
`Member, ESCMID Biofilm Study Group, April 2006, current
`Secondary Appointment, Dept. of Biological Sciences at the
`School of Dentistry, Case Western Reserve University, March
`2006, current
`Grant reviewer, NIDCR, NIH Special Emphasis Panel, current
`Reviewer, NIH ODCS Study Section, current
`Organizing Committee, the 6th International Conference on
`Cryptococcus and Cryptococcosis
`Organizing Committee, the 7th ASM Conference on Candida
`and Candidiasis, March 2004
`Organizing Committee member for the 6th ASM Conference
`on Candida and Candidiasis, January 2002
`Co-Associate Director of the Skin Diseases Research Center,
`current
`Chairman, Appointment and Promotion Committee, CWRU,
`current
` - Chaired and organized the Third Symposium on the Control
`of Surgical Infections/ Newer antimicrobial agents for the
`treatment of severe fungal infections section, April 1999
`Ad hoc reviewer, NIH Bacteriology Mycology 2 Study Section
`(BM2), Infectious Diseases Section, NIAID, 1999
`Center for AIDS Research and International Clinical
`Coordination Committee, School of Medicine, CWRU, 1999
`Senior Leadership Advisory Group, Dept. of Dermatology,
`CWRU, 1998-present
`Departmental Comprehensive Dermatology Diagnostic Lab
`Services Committee, University Hospitals, Dept. of
`Dermatology, CWRU, 1998 – present
`Departmental Research Committee, Dept. of Dermatology,
`CWRU, 1998 – present
`
`
`
`
`
`
`
`
`
`-
`
`-
`-
`-
`-
`-
`
`Permanent member, Drug Discovery and Resistance Study
`Section, NIH, 2013-2019,
`
`
`Member, Review Committee, Hong Kong University
`Reviewer, Norway Scientific Council
`
`
`Medical Mycology Society of Americas, Executive member
`Advisor, Consensus Committee on Microbiology, CLSI
`Member, Outside Interest Committee of Case Western
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`-
`
`-
`
`-
`
`-
`
`-
`-
`
`-
`-
`-
`
`-
`
`-
`
`-
`
`-
`
`-
`
`-
`
`-
`
`-
`
`-
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 4/62
`
`

`
`-
`
`-
`
`-
`
`-
`
`
`-
`
`-
`
`-
`
`-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`-
`
`
`
`
`
`
`
`
`
`
`
`undergraduate/graduate
`
`
`
`
`
`
`
`-
`
`
`
`
`
`NIH Study Section member, NRSA Committee, Infectious
`Diseases
`Section, NIAID, 1998 – present
`Veteran Affairs Merit Review Research Awards Committee -
`Infectious Diseases, 1997 – 2000
`National Committee for Clinical Laboratory Standards -
`Subcommittee on Antifungal Susceptibility Testing (NCCLS)
`Chairman of Sub-committee of Cryptococcal Susceptibility
`Testing
`(NCCLS), 1997 – to date
`Chairman of working group Antifungal Susceptibility of
`Dermatophytes, 1997 – to date
`Ph.D. Committee, Department of Medicine, Harbor-UCLA
`Medical Center, 1991 – 1995
`Research Seminar Committee, St. John's Cardiovascular
`Research Center
`Ph.D. Faculty Advisory Committee, Chairman, Department of
`Medicine, Harbor-UCLA Medical Center, 1995 – 1996
`Academic Liason, Harbor-UCLA Medical Center, California
`State
`University, Long Beach (Collaborative
`
`Research Programs in Microbiology)
`Chairman of Scientific Committee, Point Vicente Elementary
`School, Palos Verdes, CA
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Prior to relocating to the U.S.A.:
`
`
`-
`Department of Botany and Microbiology, Acting Chairman
`
`
`-
`Biological Society - Faculty of Science-Chairman
`
`
`-
`Biological Studies-Club Advisor
`
`
`-
`National Committee for Laboratory Standards - Ministry of
`Public Health, Kuwait
`Department Committee for Planning and Construction
`Seminar and Scientific Discussion Committee, Chairman
`Microbial Culture Collection Unit, Member
`Department Committee for Continued Training of Technical
`Personnel
`Master Program Committee
`Laboratory and Instrumentation Committee, Chairman
`National Committee for Laboratory Standards - Ministry of
`Commerce and Industry
`Scientific Research Committee, Member
`Botany and Microbiology Department, Secretary
`Department Committee for Curricula, Member
`National Committee for Management of Infections in Cancer
`Patients, Member
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`-
`-
`-
`-
`
`-
`-
`-
`
`-
`-
`-
`-
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 5/62
`
`

`
`
`COLLABORATIVE EFFORTS WITHIN CWRU, UNIVERSITY HOSPITALS AND CLEVELAND
`CLINIC:
`
`
`1. Collaboration within the department: I have active collaborations with Drs. Baron, Lam,
`Cooper, and McCormick. These collaborations focus on understanding the human microbiome,
`influence of this microbiota on host immune status, and effect of Phtotdynamic therapy on
`fungi.
`
`
`2. Collaboration outside the department: I have established a large number of collaborations
`across CWRU including:
`
`i. AIDS Clinical Trials Unit/ Center for AIDS Research: Michael Lederman and Benigno
`
`Rodriquez
`
`ii. Infectious Diseases: Robert Salata.
`
`iii. Pediatric Infectious Diseases: Grace McComsey
`
`iv. Eye Institute: Eric Pearlman and Loretta Szczotka
`
`v. Biomedical Engineering: James Anderson
`
`vi. Cleveland Clinic, Cancer Genomic Institute: Dr. Charis Eng
`
`vii. Division of Gastroenterology and Liver Disease: Fabio Cominelli
`
`viii. System Biology: Mark Chance
`
`ix. Akron General Hospitals: Rick Watkins
`
`x. Biochemistry: Menachem Shoham
`
`xi. Pathology: Cliff Harding
`
`
`
`3. Participation in interdisciplinary programs:
`We are part of a number of programs including:
`1)
`AI-U01-68636 AIDS Clinical Trials Network. Harvard University (Kuritzkes, PI)
`OHARA: Oral Complications of HIV.
`U01 (Lederman) 2/28/2013 - 1/31/2018
`2)
`Effects of IL-6 blockade in treated HIV infection. The major goal of this project is to
`establish the position of heightened IL-6 exposure on the pathways of pathogenesis
`and morbidity in treated HIV-1 infection.
`
`
`
`3. NIGMS National Centers for Systems Biology
`PAR-13-351 (http://grants.nih.gov/grants/guide/pa-files/PAR-13-351.html)
` CASE SYSTEMS BIOLOGY CENTER (CSBC)
`
`
`
`
`
`
`THEME: Translational systems biology for complex disease with a focus on biomarkers for
`clinical outcomes and discovery of viable drug targets
`PIs: Mark Chance, Jill Barnholtz-Sloan and Mehmet Koyuturk
`
`
`
`TRANSLATIONAL RESEARCH
`
`
`
`i. Based on my biofilm research, I co-founded a company (Great Lakes
`
`
`
`
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 6/62
`
`

`
`Pharmaceuticals, Inc.; GLPI) and developed B-lock™, an antibiofilm product. Currently,
`
`
`this product is being tested in a Phase III clinical trial following the 505(b)(2)
`
`regulatory
`
`
`route (see below).
`
`
`
`ii. Submitted invention disclosure to the Tech Transfer office regarding use of catheter
`
`Lock solutions to treat microbial biofilms.
`
`
`
`iii. Submitted invention disclosures to the Tech transfer office regarding metabolomics
`
`profile of head and neck cancer
`
`
`
`iv. Submitted invention disclosure to the Tech Transfer office regarding the use of
`
`Pichia
`and its product as a probiotic and/or therapeutic for the treatment of fungal
`infections.
`
`
`
`v. I am on a patent application for the use of photodynamic as a therapy
`
`
`
`
`
`
`ENTREPRENEURIAL ACTIVITIES:
`o Great Lakes Pharmaceuticals – Chief Scientific Officer and Co-
`Founder
` Translational research
`led
`to
`the
`founding of Great Lakes
`Pharmaceuticals, which is developing an anti-biofilm, lock solution
`that was based on my RO1 on microbial biofilms. The drug is in a
`phase III clinical trial.
` As Chief Scientific Officer, conducted pre-clinical in vitro and in vivo
`studies, in support of IND
` Personally wrote SBIR grants resulting in $2.7 million of Fast Track
`funding
` Part of team that raised private financing through angel investors,
`public funding sources (e.g. Jump Start), professional angels (e.g.
`North Coast Angels), and venture capital (Charter Life Science
`Fund)
` Published and presented abstracts and papers in support of the
`research and resulting product
`o Oasis Consumer Healthcare LLC/ARMS Pharmaceutical – Chief
`Scientific Officer and co-founder of related companies
` Developer of consumer and pharmaceutical germ remediation and
`infectious disease drugs
` Conducted pre-clinical in vitro and in vivo studies
` Oversaw Phase II clinical trial, and development of Phase III clinical
`trial
` Part of team that raised almost $8 million in private financing
`through angel investors
`investment bankers
` Developed relationships with
`strategic partnerships with industry
`
`to
`
`identify
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 7/62
`
`

`
`o Other Industry Activities
`
` Consultant and member of scientific advisory boards for large span
`of pharmaceutical and biotech industries, including Pfizer, Novartis,
`Astellas, Bristol-Myers Squibb, Schering Plough, and Merck
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PROFESSIONAL ASSOCIATIONS
`
`
`
`-
`European Society of Clinical Microbiology and Infectious
`
`
`
`
`Diseases
`
`
`
`
`
`(ESCHMID), Member
`
`
`
`-
`American Society for Microbiology, Member
`
`
`
`-
`Infectious Diseases Society of America, Fellow
`-
`American Academy of Dermatology, Memeber
`-
`International Society for Human and Animal Mycology
`
`(ISHAM), Member
`-
`Leaders Society of the Dermatology Foundation, Former
`Member
`Society for Investigative Dermatology (SID), Former Member
`The Society for General Microbiology, U.K., Former Member
`The Institute of Biology, UK (MI Biol.), Former Member
`The Institute of Medical Laboratory Science, Former Member
`American Association for the Advancement of Sciences, Former
`Member
`
`
`-
`-
`-
`-
`-
`
`-
`
`
`HONORS AND SPECIAL AWARDS
`
`
`(1) Awarded an unrestricted $500,000 grant through the “Freedom to Discover
`Award” from Bristol Myers-Squibb,
`(2) Awarded the Kuwait Foundation for Advancement of Science Award, awarded to
`recognize
`intellectual achievements
`that serve
`the
`interest of scientific
`advancement and support efforts to raise the standard of culture in various
`scientific fields,
`(3) Awarded the Billy Cooper Award from the Medical Mycological Societies of the
`Americas,
`(4) Appointed as a Chair of the Antifungal Sub-committee of the Clinical and
`Laboratory Standards
`Institute, national consensus organization, and a
`permanent member of the Drug Development and Resistant NIH study section
`till 2019,
`(5) Named one of Cleveland’s “Most Interesting People” for 2013 by Cleveland
`Magazine.
`(6) Received Prevent Blindness America Investigator Award. “Prevention of Contact
`Lens Associated Fusarium Biofilms”.
`(7) Federal Drug Administration, Invitd to participate in “Contact Lens Microbiology
`Workshop in Silver Springs, Maryland. 2009
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 8/62
`
`

`
`for
`
`
`
`
`
`(8) Special Emphasis Panel grant reviewer, Multidisciplinary Research on Oral
`Manifestations Associated with HIV/AIDS. NIDCR, National Institutes of Health,
`2008
`(9) Study Section Member, Oral Biology Small Business Special Emphasis Panel,
`National Institutes of Health, 2004
`(10) Bristol-Myers Squibb Infectious Diseases Selection Committee member, 2004
`(11) Food and Drug Administration: Invited to present to the Nonprescription Drugs and
`Dermatologic and Ophthalmic Drugs Advisory Committee member. 2004
`(12) Australian Society for Antimicrobials, Honorary Member, 2002
`(13) Wakeman Foundation for Microbiology Lecturer for the American Society for
`Microbiology, July 1999 – June 2001
`(14) Fellow of the Infectious Disease Society of America
`(15) Veterans Affairs Merit Review Subcommittee
`Washington, DC, October 1998 – present
`(16) Veterans Affairs Merit Review Research Awards Committee - Ad hoc member,
`1997-2000
`(17) Chaired Session, Fifth International Summit on Cutaneous Antifungal Therapy:
`Update on management and new therapy for the clinician. Singapore, June 1998
`(18) Chaired Session, Fungal Interactions with Host Cells. Annual General Meeting of
`the American Society for Microbiology, Atlanta, Georgia, May 1993
`(19) A.H. Shawman Prize for Biological Sciences, 1988. Awarded
` to Arab scientists for excellence in biological science research
`
`
`
`REVIEWER:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Infectious Diseases.
`
`-
`-
`-
`-
`
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`
`Clinical Microbiology and Infection
`Federation of European Microbiologists Yeast Research
`Applied and Environmental Microbiology
`Journal of the European Academy of Dermatology and
`
`Venereology
`British Journal of Dermatology
`National Institutes of Health Boards
`Chemosphere Journal
`Journal of Dental Research
`Jordan Journal of Biological Sciences
`Clinical Microbiology Reviews
`Federal Drug Administration
`Drugs Journal
`Infection and Immunity
`Eukaryotic Cell
`Journal of Antimicrobial Agents
`Environmental Research Journal
`Antimicrobial Agents and Chemotherapy
`Journal of Clinical Microbiology
`Infection Control and Hospital Epidemiology
`Mycopathologia
`Environmental Research
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 9/62
`
`

`
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`
`Editorial Board Member:
`
`
`
`-
`
`
`
`-
`-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`-
`
`-
`
`-
`
`-
`-
`
`-
`
`-
`
`
`
`Journal of Chemotherapy
`Canadian Ministry of Health
`State of Indiana Grant Review
`Public Library of Science Pathogens
`Skin Pharmacology and Physiology
`AIDS
`Infectious Disease Society of America
`Journal of Infection
`Blackwell Publishing
`Elsevier
`Yeast
`Infectious Diseases in Clinical Practice
`Cellular Microbiology
`Journal of Antimicrobial Chemotherapy
`Trends in Microbiology
`Journal of General Microbiology
`Journal of Medical Mycology
`Journal of Biomedical Materials Research
`Journal of Biological Chemistry
`Clinical Infectious Diseases
`Journal De Mycologie Medical, Editorial Board (Pasteur
`Institute, France)
`
`Journal of Chemotherapy, Editorial Board, February 2008
`The Open Proteomics Journal, October 2007 - current
`Antimicrobial Agents and Chemotherapy, October 2007 -
`current
`Journal of Chemotherapy, Microbiology and Infectious
`Diseases – Member, Editorial Advisory Board, 1st issue in
`July 2007 - present
`Open Mycology Journal (Bentham Science Publishers) 2007
`current
`Mycoses – Deputy Editor, Antimycotic Therapy, March 2006 –
`current
`Journal of Clinical Microbiology - current
`Clinical Microbiology Reviews - Reappointed January 2005
`through December 2007
`Antimicrobial Agents and Chemotherapy – appointed January
`2002 through December 2004
`Journal of Medical Mycology, Associate Editor (official
`publication of the International Society for Human and Animal
`Mycology)
`
`
`
`INVITED PROFESSIONAL ADVISOR/CONSULTANT WITH PHAREMACEUTICAL AND
`BIOTECH INDUSTRY PARTNERS
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 10/62
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`
`-
`
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`-
`
`-
`
`-
`
`-
`
`
`
`Astellas Pharmaceuticals, Chicago, Advisory Board
`Novartis, Pharma, Switzerland, Consultant
`Pfizer Pharmaceuticals, New York, Advisory Panel
`Meiji Pharmaceuticals, Tokyo, Japan, Advisory Board
`Galderma, France, Consultant
`Anacor, Palo Alto, Consultant
`
`Biosergen, Norway, Consultant
`Member, Advisory Board for Viamet Pharmaceuticals
`Member, Advisory Board for Merz Pharmaceuticals
`Maruho, Osaka, Japan, Advisory Board
`Glaxo-Smith Kline-Stiefel laboratories, Advisory Board
`Schering Plough, Advisory Board
`Polichem, Switzerland, Advisory Board
`NovaBay, Emerville, CA, Advisory Board
`Biolectrics Pharmaceutical, Cleveland, Consultant
`Gebauer, Cleveland, Consultant and collabnorator
`Enzon Pharmaceuticals, Bone Marrow Transplant Advisory
`Board
`Adaptive Therapeutics, Inc. on development of topical
`antifungals
`PCovery, Denmark, Consultant.
`ViraCor Biotechnologies, Tennessee.
`Novartis Consumer Health, Inc.,Lyon, France. Advisory Board
`Medicis, Consultant
`
`Mitotix, Inc., Consultant
`Scriptgen Pharmaceuticals, Inc., Consultant
`Biofor, Inc., Antifungal drug discovery
`Vestar, Inc., Consultant
`Zeneca, Inc. Evaluation of a novel antifungal agent
`Panax Pharmaceuticals Co., Antifungal drug discovery
`Advisory Board: International Guidelines for the Management
`of Invasive Candidiasis. Torrance.
`Consensus Conference: Diagnosis and Treatment of
`Oropharyngeal Candidiasis in Patients at Risk: A Critical
`Reassessment. San Francisco, CA.
`Quintiles, Inc. Advisory Board for anti-Infectives therapeutics
`group.
`Hoechst Marion Roussel, Inc.: Faculty member on Advisory
`Board for Antifungals.
`
`
`
`OTHER PROFESSIONAL ACTIVITIES
`
`a) Courses Taught at University Level
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 11/62
`
`

`
`General Microbiology
`Introduction to Biochemistry
`Environmental Microbiology
`Microbiological Analysis of Water
`
`Microbial World
`Microscopy and Micro-techniques
`Microbial Chemistry
`Fermentation
`Industrial Microbiology
`Microbial Physiology
`Research Course in Microbiology
`
`Microbial Physiology
`
`Return to Basic Sciences, Course ME116, 1992-1993, 1993-
`
`Fungal Pathogenesis: Role of Adherence and Phospholipase
`
`
`
`Disease Process, BMSC260A-001, 1992-1996
`
`Basic Mycology Workshop and Review for Dermatologists on
` “Introduction to mycology and opportunistic fungal infections”
`Mentoring undergraduate students
`Advising research students and postdoctoral fellows
`Undergraduate research course in biology, topic: DNA typing
`of Trichophyton rubrum, culturing and handling of pathogenic
`fungi
`Biological Basis of Disease I, Medical Mycology, 1st year med.
`students
`Introduction to Medical Mycology, Type B elective, 3rd & 4th year
`Dermatology Board Review Course, Dermatophytes
`Mycology I
`Mycology II
`Cutaneous Mycoses
`
`
`Higher Institute of
`Technology, Malta
`
`
`
`
`
`
`
`
`
`University of Kuwait,
`Kuwait
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`California State
`
`University - Long Beach
`
`UCLA
`1994
`
`
`UC Riverside
`
`CWRU
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 12/62
`
`

`
`RESEARCH PAPERS (PEER REVIEWED)
`
`1. Ghannoum MA, Moore K, Abu-Lisan M, and Walters AH. 1980. Bi-lingual and
`audio-visual aids for technical education in developing Arab countries. Laboratory
`Practice 31:50-56.
`
`
`2. Ghannoum MA, Moore K, Al-Dulaimi M, and Nasr H. 1981. The incidence of water-
`related diseases in the Brak area, Libya, from 1977 to 1979, before and after the
`installation of water treatment plants. Abl. Bakt. Hyg. I. Abt. Orig. B. 173:501-508.
`
`
`3. Ghannoum MA, Moore K, and Walters AH. 1981. An example of the conversion of
`buildings into specialized laboratories in the Third World. Laboratory Practice 30:21-
`24.
`
`
`4. Walters AH, Ghannoum MA, Abu-Lisan M, and Moore K. 1981. Environmental
`technological education in a developing country - Libya. The Environmentalist 1:133-
`143.
`
`
`5. Ghannoum MA. 1983. Microbiological spoilage of pharmaceutical preparations. J.
`Kuwait. Pharm. Assoc. 3:8-12.
`
`
`6. Zainal AS, Ghannoum MA, and Sallal AK. 1983. Microbial biodeterioration of
`leather and
`leather-containing exhibits
`in Kuwait National Museum.
`
`In
`"Biodeterioration". T.A. Oxley and S. Barry (eds), Vol. 5, John Wiley & Sons Ltd.,
`London. pp. 416-426.
`
`
`7. Safer AM and Ghannoum MA. 1983. Morphological alterations in microorganisms
`in the presence of sea water from the Arabian Gulf. Microbios. Letts. 24:65-68.
`
`
`8. Ghannoum MA, Eweiss NF, Bahajaj A, and Qureshi MA. 1983. Antimicrobial
`activity of some thiol-containing heterocycles. Microbios. 37:151-159.
`
`
`9. Ghannoum MA, Sharif H, and Al-Ghareer. 1984. Sensitivity of clinical yeasts
`isolated in Kuwait against a number of antifungal agents. Mykosen 27:402-410.
`
`
`10. Ghannoum MA and Al-Khars A. 1984. Effect of antineoplastic agents on the
`growth and ultrastructure of Candida albicans. Mykosen 27:452-464.
`
`
`11. Ghannoum MA, Mudher A, and Burns G. 1985. Incorporation of dexamethasone
`by Candida albicans. Microbios. 42:103-109.
`
`
`12. Ghannoum MA, Khattar MM, Kayed F, and Shridar S. 1985. The influence of anti-
`neoplastic agents on experimental candidosis in mice. Mykosen 28:369-387.
`
`
`13. Ghannoum MA, Bowman WR, and Valmas M. 1985. Anti-microbial activity of some
`heterocyclic derivatives of 1-methyl-1-nitroethyl sulphides. Microbios. 42:211-223.
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 13/62
`
`

`
`
`14. Ghannoum MA, Motawy MS, Mubarak A, and Al-Awadhi H. 1985. Candida
`albicans strain differentiation in cancer patients undergoing therapy. Mykosen
`28:388-393.
`
`
`15. Ghannoum MA, Burns G, and Abu-Elteen K. 1985. Candida albicans in
`dexamethasone-supplemented media. Sabouraudia 23:313-315.
`
`
`16. Ghannoum MA, Motawy MS, Mubarak A, and Al-Awadhi H. 1985. Incidence and
`susceptibility of yeasts isolated from cancer patients in Kuwait. Mykosen 28:619-
`624.
`
`
`17. Ghannoum MA, Thompson MM, Bowman WR, and Al-Khalil SI. 1986. The mode
`of action of the antimicrobial compound 5-bromo-5-nitro-1, 3-dioxane (bronidox).
`Folia Microbiologica 1:19-31.
`
`
`18. Ghannoum MA, Janini G, Khamis L, and Radwan SS. 1986. Dimorphism-
`associated variations in the lipid composition of Candida albicans. Journal of
`General Microbiology 132:2367-2375.
`
`
`19. Ghannoum MA, Burns GR, Abu-Elteen K, and Radwan SS. 1986. Experimental
`evidence for the role of lipids in adherence of Candida spp. to human buccal
`epithelial cells. Infection and Immunity 54:189-193.
`
`
`20. Ghannoum MA and Abu-Elteen K. 1986. Correlative relationship between
`proteinase production, adherence and pathogenicity of various strains of Candida
`albicans. Journal of Medical and Veterinary Mycology 24:407-413.
`
`
`21. Ghannoum MA. 1986. Effects of anti-neoplastic agents on growth, morphology and
`metabolism of Torulopsis glabrata. Mycopathologia 95:175-181.
`
`
`22. Ghannoum MA and Abu-Elteen K. 1987. Effect of growth of Candida spp. in the
`presence of various glucocorticoids on the adherence of Candida spp. to human
`buccal epithelial cells. Mycopathologia 98:171-178.
`
`
`23. Al-Hasan RH, Ghannoum MA, Sallal AK, Abu-Elteen KH, and Radwan SS. 1987.
`Correlative changes of growth, pigmentation and lipid composition of Dunaliella
`salina in response to halostress. Journal of General Microbiology 133:2607-2616.
`
`
`24. Sallal AK, Ghannoum MA, Al-Hasan RH, Nimer NA, and Radwan SS. 1987.
`Lanosterol and diacylglycerophosphocholines in lipids from whole cells and
`thylakoids of the cyanobacterium Chlorogloeopsis fritschii. Archives of Microbiology
`148:1-7.
`
`
`25. Ghannoum MA, Abu-Elteen K, and Radwan SS. 1987. Blocking the adherence of
`Candida albicans to buccal epithelial cells by yeast and mycelial and total lipids from
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 14/62
`
`

`
`the epithelial cells. Mykosen 30:371-378.
`
`
`26. Ghannoum MA, Thompson M, Beadle CD, and Bowman WR. 1988. Anti-bacterial
`activity of some alpha-substituted 2-methyl-5-nitrofurans. Folia Microbiologia 33:198-
`207.
`
`
`27. Ghannoum MA. 1988. Mechanisms potentiating Candida infections. A review.
`Mycoses 31:543-557.
`28. Ghannoum MA. 1988. Studies on the anti-candidal mode of action of Allium
`sativum (Garlic). Journal of General Microbiology 134:2917-2924.
`
`
`29. Ghannoum MA, Abu-Elteen KH, and Motawy MS. 1988. Effect of antineoplastic
`agents and X-irradiation on the adherence of Candida spp. to human buccal
`epithelial cells in vitro. Mycopathologia 104:171-180.
`
`
`30. Ghannoum MA, Motawy MS, Abu Hatab MA, Ibrahim AS, and Criddle RS. 1989.
`Multifactorial analysis of interactions among anti-fungal and anti-neoplastic drugs on
`inhibition of Candida albicans growth. Antimicrobial Agents and Chemotherapy
`33:717-725.
`
`
`31. Ghannoum MA, Motawy MS, Abu Hatab MA, Abu-Elteen KH, and Criddle RS.
`1989. Interactive effects of antifungal and antineoplastic agents on yeast commonly
`prevalent in cancer patients. Antimicrobial Agents and Chemotherapy 33:726-730.
`
`
`32. Ghannoum MA, Afzal M, Hasan RA, and Dhami MS. 1989. Variation in growth and
`fatty acid contents of Trichoderma viride induced by herbicides. Journal of
`Environmental Science and Health 24:89-90.
`
`
`33. Mulder JL, Ghannoum MA, Khamis L, and Abu-Elteen KH. 1989. Growth and lipid
`composition of some dematiaceous hyphomycetes fungi grown at different salinities.
` Journal of General Microbiology 135:3393-3413.
`
`
`34. Ghannoum MA, Abu-Elteen KH, and El-Rayyes NR. 1989. Antimicrobial activity of
`some 2-aminopyridines. Microbios 60:23-35.
`
`
`35. Abu-Elteen KH, Ghannoum MA, and Stretton RJ. 1989. Effects of sub-inhibitory
`concentrations of anti-fungal agents on adherence of Candida spp. to buccal
`epithelial cells in vitro. Mycoses 32:551-562.
`
`
`36. Sorkhoh NA, Ghannoum MA, Ibrahim AS, Stretton RJ, and Radwan SS. 1990.
`Crude oil and hydrocarbon-degrading strains of Rhodococcus rhodochrous isolated
`from soil and marine environments in Kuwait. Environmental Pollution 65:1-17.
`
`
`37. Sorkhoh NA, Ghannoum MA, Ibrahim AS, Stretton RJ, and Radwan SS. 1990.
`Sterols and diacylglycerophosphocholines in the lipids of the hydrocarbon-utilizing
`prokaryote Rhodococcus rhodochrous. Journal of Applied Bacteriology 69:856-863.
`
`CFAD v. Anacor, IPR2015-01776 ANACOR EX. 2029 - 15/62
`
`

`
`
`38. Sorkhoh NA, Ghannoum MA, Ibrahim AS, Stretton RJ, and Radwan SS. 1990.
`Growth of Candida albicans on hydrocarbons: influence on lipids and sterols.
`Microbios. 64:159-171.
`
`
`39. Ghannoum MA. 1990. Inhibition of Candida adhesion to buccal epithelial cells by
`Allium sativum (Garlic). Journal of Applied Bacteriology 68:163-171.
`
`
`40. Ghannoum MA, Abu-Elteen KH, Ellabib M, and Whittaker PA. 1990. Antimycotic
`effects of octenidine and pirtenidine. The Journal of Antimicrobial Chemotherapy
`25:237-245.
`
`
`41. Moussa NM, Ghannoum MA, Whittaker PA, El-Ezaby MS, and Quaraman S. 1990.
` Effects of cisplatin and two novel palladium complexes on Candida albicans.
`Microbios. 62:165-178.
`
`
`
`42. Ghannoum MA and Abu-Elteen KH. 1990. Pathogenicity determinants in Candida:
`A review. Mycoses 33:265-282.
`
`
`43. Ghannoum MA, Swairjo I, and Soll DR. 1990. Variation in lipid and sterol contents
`in Candida albicans white and opaque phenotypes. Journal of Medical and
`Veterinary Mycology 28:103-117.
`
`
`44. Ghannoum MA, Abu-Elteen KH, Motawy M, Abu-Hatab MA, Ibrahim A, and Criddle
`R. 1990. Combinations of antifungal and antineoplastic drugs with interactive effects
`on inhibition of yeast growth. Chemotherapy 36:308-320.
`
`
`45. Ghannoum MA, Abu-Elteen KH, Stretton RJ, and Whittaker PA. 1990. Effects of
`octenidine and pirtenidine on adhesion of Candida spp. to buccal epithelial cells in
`vitro. Archives of Oral Biology 35:249-253.
`
`
`46. Ellabib M, Ghannoum MA, and